(NASDAQ: TNYA) Tenaya Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Tenaya Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast TNYA's revenue for 2025 to be $2,444,641,530, with the lowest TNYA revenue forecast at $2,444,641,530, and the highest TNYA revenue forecast at $2,444,641,530. On average, 1 Wall Street analysts forecast TNYA's revenue for 2026 to be $3,259,522,040, with the lowest TNYA revenue forecast at $3,259,522,040, and the highest TNYA revenue forecast at $3,259,522,040.
In 2027, TNYA is forecast to generate $46,342,254,604 in revenue, with the lowest revenue forecast at $8,148,805,100 and the highest revenue forecast at $84,535,704,107.